GNTX GENTEX CORP

Nasdaq gentex.com


$ 26.72 $ -0.18 (-0.69 %)    

Friday, 17-Oct-2025 17:43:38 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 26.01
$ 26.20
$ 26.13 x 1
$ 26.86 x 2
$ 25.98 - $ 26.50
$ 20.08 - $ 30.86
4,580,854
na
5.71B
$ 0.89
$ 14.23
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-01-2024 09-30-2024 10-Q
5 08-02-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-22-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-01-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-03-2019 03-31-2019 10-Q
27 02-22-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-21-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-04-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 02-22-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-23-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ubs-maintains-neutral-on-gentex-raises-price-target-to-29

UBS analyst Joseph Spak maintains Gentex (NASDAQ:GNTX) with a Neutral and raises the price target from $28 to $29.

 ubs-maintains-neutral-on-gentex-raises-price-target-to-28

UBS analyst Joseph Spak maintains Gentex (NASDAQ:GNTX) with a Neutral and raises the price target from $23 to $28.

 b-riley-securities-maintains-buy-on-gentex-raises-price-target-to-32

B. Riley Securities analyst Josh Nichols maintains Gentex (NASDAQ:GNTX) with a Buy and raises the price target from $28 to $32.

 baird-maintains-neutral-on-gentex-raises-price-target-to-30

Baird analyst David Leiker maintains Gentex (NASDAQ:GNTX) with a Neutral and raises the price target from $26 to $30.

 us-stocks-hit-new-highs-as-magnificent-seven-reach-19-trillion-whats-moving-markets-friday

Wall Street looked set to close the week on a high note, with large-cap benchmarks pushing higher in Friday's midday tradin...

 why-gentex-stock-is-gaining-today

Gentex shares jumped 15% after beating Q2 estimates, boosting full-year sales guidance, and posting strong margins despite weak...

 gentex-raises-fy2025-sales-guidance-from-2150b-2320b-to-2440b-2610b-vs-2435b-est

Gentex (NASDAQ:GNTX) raises FY2025 sales outlook from $2.150 billion-$2.320 billion to $2.440 billion-$2.610 billion vs $2.435 ...

 gentex-q2-eps-043-beats-037-estimate-sales-657858m-beat-604874m-estimate

Gentex (NASDAQ:GNTX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.37 by 16.22...

 earnings-preview-for-gentex
Earnings Preview For Gentex
07/24/2025 15:01:12

 ubs-maintains-neutral-on-gentex-raises-price-target-to-23

UBS analyst Joseph Spak maintains Gentex (NASDAQ:GNTX) with a Neutral and raises the price target from $21 to $23.

 baird-maintains-neutral-on-gentex-raises-price-target-to-26

Baird analyst David Leiker maintains Gentex (NASDAQ:GNTX) with a Neutral and raises the price target from $25 to $26.

 gentex-q1-impacted-by-tariff-uncertainty-suspends-mirror-production-for-chinese-market

Gentex shares fall as Q1 results reflect tariff pressures, prompting a halt in China-bound mirror production and a lowered 2025...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION